The European Union’s antitrust regulators have blocked a planned merger between genetic sequencing company Illumina, Inc. and cancer detection test manufacturer Grail, Inc.
The $7.1bn merger was rejected in Europe on 1 September, just days after the administrative law judge presiding over the...






